Abstract LB-408: an Integrative Genomic Approach Uncovers Oncogenic Roles of YY1-signaling in Hepatocellular Carcinoma with Stem Cell-Like Traits

Xuelian Zhao,Stephanie Roessler,Anuradha Budhu,Zhipeng Yu,Huliang Jia,Qinghai Ye,Lunxiu Qin,Zhaoyou Tang,Xin Wei Wang

DOI: https://doi.org/10.1158/1538-7445.am2012-lb-408

IF: 11.2

2012-01-01

Cancer Research

Abstract:Abstract Hepatocellular carcinoma (HCC) is an aggressive solid tumor with vast heterogeneity in its clinical presentation and tumor biology. Genomic and transcriptomic analyses have revealed numerous HCC subtypes that are associated with patient outcome. Recently, we have identified a subset of aggressive HCC with stem cell-like traits and elevated levels of EpCAM and AFP (EpCAMhigh/AFPhigh). To identify key pathways contributing to this subset of HCCs, we used an integrated genomic strategy by comparing gene expression profiles of a well-defined HCC cohort consisting of 38 EpCAMhigh/AFPhigh and 40 EpCAM−/AFP− HCC cases using Affymetrix U133A array analyses. We identified a robust gene expression signature that can classify these two subgroups and is predictive of HCC prognosis. We validated this signature as an independent predictor of patient survival in two additional independent cohorts of HCC samples with mixed etiologies and ethnicity. Gene Set Enrichment Analysis revealed that genes containing YY1 transcriptional factor binding sites are most significantly enriched in the signature, suggesting that the YY1 signaling pathway may be functionally critical in regulating stem cell-like HCC. Genomic analysis using the Agilent 105A human arrayCGH platform revealed that the YY1 co-activator gene YY1AP1, but not YY1, is highly amplified in a majority of EpCAMhigh/AFPhigh HCCs (85%). YY1AP1 expression in HCC was significantly correlated with its genomic amplification and was also associated with patient prognosis. Using a lentiviral construct expressing YY1AP1 shRNA either constitutively or inducibly via tetracycline, we found that silencing of YY1AP1 completely blocked the growth of EpCAMhigh/AFPhigh HCC cell lines that contain YY1AP1 gene amplification. Furthermore, we found that YY1 transcriptionally activated YY1AP1-dependent EpCAM expression. In parallel, silencing of EpCAM via RNA interference also inhibited HCC cell growth. Our results suggest that YY1-YY1AP1 signaling is an oncogenic driver critical to the development of stem cell-like HCC through activation of EpCAM. Our results also demonstrate the feasibility and power of our strategy to utilize well-defined patient samples to uncover critical pathways linked to HCC subtypes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-408. doi:1538-7445.AM2012-LB-408